If pain or inflammation is experienced, treatment should be discontinued.
Indication
Indicated as an aid in the removal of ear wax.
Contra Indication
Contraindicated in patients with perforation of the ear drum or inflammation of the ear.
Dose
N/A
Side Effect
Immune system disorders: hypersensitivity/allergic reactions; Skin disorders: contact dermatitis and allergic skin reactions; General disorders: Application site reactions rarely including transient stinging or irritation may occur.
Pregnancy Category
Name :
Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.
Mode of Action
Ear wax which often obstructs the external auditory meatus of the ear contains less than 50% of fatty matter derived from secretions of the sebaceous ceruminous glands. The majority of the wax consists of desquamated epithelium, foreign matter and shed hairs. This non-fatty material forms a matrix holding together the granules of fatty matter to form the ceruminous mass.
The addition of oils or solvents binds the mass more firmly together, but aqueous solutions, if they are able to penetrate the matrix, cause a disintegration of the ceruminous mass. Docusate ear drops, because of their low surface tension and miscibility, rapidly penetrate the dry matrix of the ceruminous mass, reducing the solid ear wax to a semi-solid debris.
Interaction
Interaction with other medicinal products and other forms of interaction: None known.
Pregnancy Category Note
Docusate can be used in case of pregnancy & lactation. As it is a non -systemic application, there is no information to suggest that Docusate ear drops should not be used during pregnancy and lactation.
Adult Dose
Adults (including the elderly):
Apply Docusate ear drops sufficient to fill (approx. 10 drops) the affected ear for two consecutive nights.
Child Dose
Children (from 1 year):
Apply Docusate ear drops sufficient to fill (approx. 10 drops) the affected ear for two consecutive nights.
Renal Dose
No information is available from controlled clinical studies regarding the use of this drugs in patients with advanced renal disease.
Administration
Topically administration into ear
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.